FINWIRES · TerminalLIVE
FINWIRES

Procept BioRobotics Enrolls 280 Patients in WATER IV Prostate Cancer Study

By

Procept BioRobotics (PRCT) enrolled 280 patients in the WATER IV study evaluating its Aquablation therapy against radical prostatectomy for prostate cancer.

The company said Thursday it expects to present the primary endpoint results from the study at the American Urological Association annual meeting in spring 2027.

Procept also received Investigational Device Exemption approval from the US Food and Drug Administration for a second randomized protocol comparing Aquablation therapy with active surveillance in men with Grade Group 1 and 2 prostate cancer. The study will enroll up to 333 patients globally, the company said.

Both studies will follow patients for 10 years to assess disease control and quality-of-life outcomes, Procept said.

Price: $26.12, Change: $-0.35, Percent Change: -1.30%

Related Articles

Wire

Dell Technologies Unit Wins $9.69 Billion US Navy Contract

Dell Technologies (DELL) unit Dell Federal Systems won a blanket purchase agreement with an overall estimated value of $9.69 billion from the US Navy under the Department of Defense Enterprise Software Initiative.The agreement will streamline software acquisition across the Defense Department, the intelligence community, and the US Coast Guard, according to a statement.The deal will allow clients to procure Microsoft (MSFT) software licenses, cloud subscriptions, and Software Assurance, according to the Department.

$DELL$MSFT
Wire

Dave to Replace American Woodmark in S&P SmallCap 600

Dave (DAVE) is set to replace American Woodmark (AMWD) in the S&P SmallCap 600 before trading begins Monday, S&P Dow Jones Indices said.MasterBrand (MBC) is acquiring American Woodmark in a deal expected to close May 29, the S&P Global (SPGI) unit said Wednesday in a statement.Dave shares rose 4.2% in after-hours trading.

$AMWD$DAVE$SPGI
Wire

Citi Trends Reports Preliminary Fiscal Q1 Sales, Lifts FY Comparable-Store Sales Outlook

Citi Trends (CTRN) reported fiscal Q1 preliminary sales late Wednesday of $230.9 million and raised its full-year outlook for comparable-store sales growth.A year earlier, sales were $201.7 million.Comparable-store sales growth in fiscal 2026 is expected to range from 8% to 10%, compared with the prior 5% to 7% forecast, the company said.Citi Trends also lifted its full-year adjusted EBITDA guidance to $35 million to $40 million from the previous outlook of $34 million to $38 million.Citi Trends shares rose 10% in after-hours trading.

$CTRN